HCM
MREO

Highlander Capital Management’s Mereo BioPharma MREO Stock Holding History

Highlander Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$419 Hold
127
– – ﹤0.01% 900
2023
Q4 		$293 Hold
127
– – ﹤0.01% 938
2023
Q3 		$0 Buy
+127
New +$169 ﹤0.01% 925

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Highlander Capital Management's MREO Position: Q1 2024 in Review

Highlander Capital Management held its Mereo BioPharma (MREO) position steady in Q1 2024 at 127 shares worth $419. The position accounts for ﹤0.01% of the portfolio, ranked #900.

Highlander Capital Management first reported a position in MREO in Q3 2023 and has held it in 3 quarters since. 80 funds tracked by Wall St. Rank hold MREO as of Q1 2024.

  • Highlander Capital Management held 127 shares of Mereo BioPharma worth $419 as of Q1 2024.
  • Highlander Capital Management left its Mereo BioPharma share count unchanged in Q1 2024.
  • Mereo BioPharma made up ﹤0.01% of Highlander Capital Management's portfolio in Q1 2024, its #900 holding.
  • Highlander Capital Management first reported a position in Mereo BioPharma in Q3 2023 and has held it in 3 quarters since.
  • 80 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2024.

Based on Highlander Capital Management's 13F filing for Q1 2024, filed 20 May 2024.